Anaplastic thyroid cancer (ATC) is an aggressive malignancy with poor survival and limited treated options. Preclinical data suggest a possible therapeutic role for CDK4/6 inhibition. We report our clinical trial with abemaciclib, an oral CDK4/6 inhibitor, in patients with incurable ATC after FDA-approved treatment options. This phase 2 study evaluated the efficacy of oral abemaciclib, 200 mg twice daily.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile